(4S,7S,10aS)-4-Amino-7-(1,3,4-oxadiazol-2-yl)hexahydro-2H-pyrido[2,1-b][1,3]thiazepin-5(7H)-one 2,2,2-trifluoroacetate → (2R,5R)-N1-((4S,7S,10aS)-7-(1,3,4-Oxadiazol-2-yl)-5-oxooctahydro-2H-pyrido[2,1-b][1,3]thiazepin-4-yl)-2,5-dibenzyl-N6-((S)-2-oxo-1-phenylazepan-3-yl)hexanediamide

Participants

Reaction Steps

(2R,5R)—N1-((4S,7S,10aS)-7-(1,3,4-Oxadiazol-2-yl)-5-oxooctahydro-2H-pyrido[2,1-b][1,3]thiazepin-4-yl)-2,5-dibenzyl-N6-((S)-2-oxo-1-phenylazepan-3-yl)hexanediamide was synthesized as described in General Procedure H using Intermediate 24 (10 mg, 0.020 mmol) and Intermediate 35 (7.1 mg, 0.023 mmol) to give a white solid (3.5 mg, 24% yield). Anal. Calcd. for C43H50N6O5S m/z 762.7. found: 763.3 (M+H)+; 1H NMR (400 MHz, CDCl3) δ ppm 8.31 (1H, s), 7.40-7.32 (2H, m), 7.31-7.07 (13H, m), 7.02-6.90 (2H, m), 5.91 (1H, d, J=4.9 Hz), 5.27 (1H, t, J=4.4 Hz), 5.05-4.97 (1H, m), 4.78 (1H, dd, J=9.3, 6.6 Hz), 3.93 (1H, dd, J=15.1, 11.3 Hz), 3.59 (1H, dd, J=14.8, 4.9 Hz), 3.18-3.07 (1H, m), 2.90-2.68 (6H, m), 2.55 (1H, ddd, J=14.3, 5.5, 2.7 Hz), 2.46-2.33 (2H, m), 2.14-1.80 (8H, m), 1.77-1.65 (4H, m), 1.64-1.25 (4H, m).

Provenance & Evidence